Bausch + Lomb Corporation (NYSE:BLCO – Get Free Report) Director Eschenbach Andrew Von sold 6,059 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $16.58, for a total transaction of $100,458.22. Following the sale, the director directly owned 63,733 shares in the company, valued at approximately $1,056,693.14. This represents a 8.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Bausch + Lomb Price Performance
Shares of NYSE:BLCO opened at $16.81 on Thursday. The firm has a market capitalization of $6.00 billion, a price-to-earnings ratio of -35.02, a price-to-earnings-growth ratio of 0.55 and a beta of 0.56. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.55 and a quick ratio of 1.02. The business’s 50 day simple moving average is $16.13 and its 200-day simple moving average is $16.39. Bausch + Lomb Corporation has a 12 month low of $13.77 and a 12 month high of $18.92.
Hedge Funds Weigh In On Bausch + Lomb
Several hedge funds have recently bought and sold shares of the stock. Handelsbanken Fonder AB raised its holdings in shares of Bausch + Lomb by 5.3% in the second quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company’s stock worth $364,000 after acquiring an additional 1,100 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Bausch + Lomb by 16.0% during the first quarter. Bank of America Corp DE now owns 65,765 shares of the company’s stock valued at $1,046,000 after acquiring an additional 9,066 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Bausch + Lomb by 67.1% during the first quarter. Royal Bank of Canada now owns 3,657 shares of the company’s stock valued at $58,000 after acquiring an additional 1,468 shares during the last quarter. Whitebox Advisors LLC increased its position in Bausch + Lomb by 15.8% during the 1st quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock worth $17,519,000 after purchasing an additional 150,641 shares in the last quarter. Finally, Sei Investments Co. increased its position in Bausch + Lomb by 100.0% during the 1st quarter. Sei Investments Co. now owns 139,266 shares of the company’s stock worth $2,214,000 after purchasing an additional 69,633 shares in the last quarter. Hedge funds and other institutional investors own 11.07% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Bausch + Lomb
Bausch + Lomb Company Profile
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Featured Articles
- Five stocks we like better than Bausch + Lomb
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.
